Emergency subtotal colectomy rates in relation to anti-TNF therapy in inflammatory bowel disease patients: comparison of retrospective cohorts

References

• Sairenji T, Collins KL, Evans DV. An update on inflammatory bowel disease. Prim Care. 2017;44(4):673–692.
   PubMed Web of Science ®Google Scholar
• Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015;12(12):720–727.
   PubMed Web of Science ®Google Scholar
• Busch K, Ludvigsson JF, Ekstrom-Smedby K, et al. Nationwide prevalence of inflammatory bowel disease in Sweden: a population-based register study. Aliment Pharmacol Ther. 2014;39(1):57–68.
   PubMed Web of Science ®Google Scholar
• Burisch J, Jess T, Martinato M, et al. The burden of inflammatory bowel disease in Europe. J Crohns Colitis. 2013;7(4):322–337.
   PubMed Web of Science ®Google Scholar
• Mak WY, Zhao M, Ng SC, et al. The epidemiology of inflammatory bowel disease: East meets west. J Gastroenterol Hepatol. 2020;35(3):380–389.
   PubMed Web of Science ®Google Scholar
• Hindryckx P, Jairath V, D’Haens G. Acute severe ulcerative colitis: from pathophysiology to clinical management. Nat Rev Gastroenterol Hepatol. 2016;13(11):654–664.
   PubMed Web of Science ®Google Scholar
• Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005;128(7):1805–1811.
   PubMed Web of Science ®Google Scholar
• Reich KM, Chang HJ, Rezaie A, et al. The incidence rate of colectomy for medically refractory ulcerative colitis has declined in parallel with increasing anti-TNF use: a time-trend study. Aliment Pharmacol Ther. 2014;40(6):629–638.
   PubMed Web of Science ®Google Scholar
• Khoudari G, Mansoor E, Click B, et al. Rates of intestinal resection and colectomy in inflammatory bowel disease patients after initiation of biologics: a cohort study. Clin Gastroenterol Hepatol. 2022;20:e974–e983.
   PubMed Web of Science ®Google Scholar
• Barnes EL, Jiang Y, Kappelman MD, et al. Decreasing colectomy rate for ulcerative colitis in the United States Between 2007 and 2016: a time trend analysis. Inflamm Bowel Dis. 2020;26 (8):1225–1231.
   PubMed Web of Science ®Google Scholar
• Candido FD, Fiorino G, Spadaccini M, et al. Are surgical rates decreasing in the biological era In IBD? Curr Drug Targets. 2019;20(13):1356–1362.
   PubMed Web of Science ®Google Scholar
• Kolehmainen S, Lepisto A, Farkkila M. Impact of anti-TNF-alpha therapy on colectomy rate and indications for colectomy in ulcerative colitis: comparison of two patient cohorts from 2005 to 2007 and from 2014 to 2016. Scand J Gastroenterol. 2019;54(6):707–711.
   PubMed Web of Science ®Google Scholar
• Honap S, Pavlidis P, Ray S, et al. Tofacitinib in acute severe ulcerative colitis-A real-world tertiary center experience. Inflamm Bowel Dis. 2020;26(11):e147–e149.
   PubMed Web of Science ®Google Scholar
• Ochsenkühn T, Tillack C, Szokodi D, et al. Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis. United European Gastroenterol J. 2020;8(1):91–98.
   PubMed Web of Science ®Google Scholar
• Devaraj B, Kaiser AM. Surgical management of ulcerative colitis in the era of biologicals. Inflamm Bowel Dis. 2015;21(1):208–220.
   PubMed Web of Science ®Google Scholar
• Kin C, Kate Bundorf M. As infliximab use for ulcerative colitis has increased, so has the rate of surgical resection. J Gastrointest Surg. 2017;21(7):1159–1165.
   PubMed Web of Science ®Google Scholar
• Moore SE, McGrail KM, Peterson S, et al. Infliximab in ulcerative colitis: the impact of preoperative treatment on rates of colectomy and prescribing practices in the province of British Columbia, Canada. Dis Colon Rectum. 2014;57(1):83–90.
   PubMed Web of Science ®Google Scholar
• Narula N, Marshall JK, Colombel JF, et al. Systematic review and meta-analysis: infliximab or cyclosporine as rescue therapy in patients with severe ulcerative colitis refractory to steroids. Am J Gastroenterol. 2016;111(4):477–491.
   PubMed Web of Science ®Google Scholar
• Oh SJ, Shin GY, Soh H, et al. Long-term outcomes of infliximab in a real-world multicenter cohort of patients with acute severe ulcerative colitis. Intest Res. 2021;19(3):323–331.
   PubMed Web of Science ®Google Scholar
• Patrick D, Doecke JD, Irwin J, et al. Short‐term colectomy is avoided in over half of regional patients failing medical therapy for acute severe ulcerative colitis with co‐ordinated transfer and tertiary care. Intern Med J. 2020;50(7):823–829.
   PubMed Web of Science ®Google Scholar
• Rajan R, Trinder MW, Lo J, et al. Assessing the efficacy of TNF-alpha inhibitors in preventing emergency and emergent colectomies. JGH Open. 2020;4(2):140–144.
   PubMed Web of Science ®Google Scholar
• Szemes K, Soos A, Hegyi P, et al. Comparable long-term outcomes of cyclosporine and infliximab in patients with steroid-refractory acute severe ulcerative colitis: a meta-analysis. Front Med (Lausanne). 2019;6:338.
   PubMed Web of Science ®Google Scholar
• Argollo MC, Kotze PG, Spinelli A, et al. The impact of biologics in surgical outcomes in ulcerative colitis. Best Pract Res Clin Gastroenterol. 2018;32-33:79–87.
   PubMed Web of Science ®Google Scholar
• Kaplan GG, Seow CH, Ghosh S, et al. Decreasing colectomy rates for ulcerative colitis: a population-based time trend study. Am J Gastroenterol. 2012;107(12):1879–1887.
   PubMed Web of Science ®Google Scholar
• Verdon C, Reinglas J, Coulombe J, et al. No change in surgical and hospitalization trends despite higher exposure to anti-tumor necrosis factor in inflammatory bowel disease in the Québec provincial database FROM 1996 to 2015. Inflamm Bowel Dis. 2021;27(5):655–661.
   PubMed Web of Science ®Google Scholar
• Ward ST, Mytton J, Henderson L, et al. Anti-TNF therapy is not associated with an increased risk of post-colectomy complications, a population-based study. Colorectal Dis. 2018;20(5):416–423.
   PubMed Web of Science ®Google Scholar
• Billioud V, Ford AC, Tedesco ED, et al. Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis. J Crohns Colitis. 2013;7(11):853–867.
   PubMed Web of Science ®Google Scholar